a suboptimal intrauterine environment results in impaired fetal growth and leads to increased incidence of cardiovascular, metabolic, and reproductive disorders in adult life.
a suboptimal intrauterine environment results in impaired fetal growth and leads to increased incidence of cardiovascular, metabolic, and reproductive disorders in adult life. 1 an abnormal intrauterine hormonal milieu can influence clearly fetal growth and development and has been identified as a factor known to cause intrauterine programming. 2 For instance, excessive prenatal exposure to androgens causes intrauterine growth restriction, hypertension, insulin resistance, reproductive disruptions, and other metabolic abnormalities, simulating the polycystic ovary syndrome (PCOS) phenotype in adult females.
adult prenatal testosterone-exposed females have higher testosterone levels, and ovariectomy not only reduces testosterone levels but also reverses BP, 4 suggesting that the presence of increased testosterone levels is essential for increasing BP. These data provide evidences that androgens may contribute to the hypertensive process in females. available data in humans also indicate that androgens can contribute to BP control in women just as in men because young women with conditions such as PCOS, postmenopausal women, 20 and black women 21, 22 have higher serum testosterone levels, and the frequency of hypertension is greater in these populations. [23] [24] [25] Thus, direct and indirect evidence implicates androgens in hypertension in females. However, the molecular mechanisms underlying androgen-mediated increases in BP remain largely unclear.
Protein kinase C (PKC) is a key regulatory enzyme involved in the signal transduction in vascular health and disease, including cell growth and contractility. [26] [27] [28] Several lines of evidence have implicated the activation of PKC-mediated signaling in pathogenesis of hypertension. [29] [30] [31] [32] For example, PKC-mediated contractile responses are enhanced in aortas of SHR but not Wistar-Kyoto rats 33, 34 ; hypertensive models, including the SHR 35, 36 and DOCa-salt hypertensive rats have increased vascular expression/activity of PKC 37 ; perfusion of hindlimb of SHR and Wistar-Kyoto rats with the PKC activator, phorbol 12,13-dibutyrate (PDBu) caused prolonged vasoconstriction and increased perfusion pressure 38 ; and PKC gene silencing normalized arterial BP in SHR. 29 These studies suggest that increased PKC expression and function may be a key molecule contributing to the development of hypertension. However, the molecular basis of activation of PKCs and the mechanisms that control the expression of PKC isozymes, especially knowledge on the functional elements in the PKC gene promoter or the nature of the factors that control PKCδ gene transcription is not well characterized.
Because testosterone is known to interact with PKC, upregulating the classical constrictor pathway via upregulation of PKC isoenzymes, 39, 40 we investigated the molecular mechanism by which testosterone transcriptionally modulates PKC expression and determined whether regulation of PKC signaling by testosterone plays an important role in mediating vascular contraction and hypertension.
Methods
all experimental procedures were performed in accordance with the National Institutes of Health guidelines (NIH Publication No. 85-23, revised 1996) with approval by the animal Care and Use Committee at the University of Texas Medical Branch. Timed-pregnant SpragueDawely rats (Harlan, Houston, TX) were divided into 2 groups on gestational day 14, and 1 group received daily injections of testosterone propionate (Sigma, St. Louis, MO) subcutaneously from gestational days 15 to 19 at 0.5 mg/kg body weight/d (n=8). The other group received vehicle (sesame oil, n=8). This dose and duration of exposure are commonly used to mimic plasma testosterone levels (2-fold increase) observed in preeclamptic women. 3, 4, 41, 42 Dams in both groups were allowed to deliver at term and the birth weights of pups were recorded. The number of pups in the control and testosterone litters were adjusted to 10 pups per dam to ensure equal nutrient access for all offspring (pups with weights at each extreme were euthanized). The ratio of male to female pups remained equivalent after culling, when possible. Pups were weaned at 3 weeks of age, and only females were used for this study. at 6 months of age, arterial pressure was monitored using the telemetry system. after BP measurements, the animals were euthanized, the plasma separated and mesenteric arteries (Mas) were isolated. a portion of the Mas was used for vascular reactivity studies, and the remaining were quickly frozen for RNa/ 
Results

Prenatal Testosterone Exposure Leads to Hyperandrogenism and Hypertension in Adult Females
Plasma testosterone levels in 6-month-old females were significantly higher by 2-fold in prenatal testosterone-exposed rats (0.84±0.04 ng/mL; n=8) compared with controls (0.42±0.09 ng/mL; n=8; P<0.05). as shown in Figure 1a and 1B, prenatal testosterone exposure significantly increased BP in adult females, as compared with control animals (P<0.05; n=6-8).
Antiandrogen Treatment and PKCδ Blockade Reverses Increased BP in Hyperandrogenic Prenatal Testosterone-Exposed Rats
Flutamide administration significantly attenuated the increased BP observed in prenatal testosterone-exposed females (Figure 1a ; P<0.05; n=6-8). Flutamide had no significant effect on BP in controls. Stopping flutamide treatment returned arterial pressure to pretreatment levels in prenatal testosterone-exposed adults (Figure 1a and 1B; P<0.05).
Inhibition of PKCδ with rottlerin abrogated increase in BP in prenatal testosterone-exposed females ( Figure 1C ; P<0.05; n=8). Rottlerin had no significant effect on BP in controls ( Figure 1C ).
PKCδ Expression Is Increased in the MAs of Hyperandrogenic Prenatal Testosterone-Exposed Females
We next determined the expression profile of PKC isozymes in the Mas. as shown in Figure 2 , quantitative real-time polymerase chain reaction shows the expression of at least 6 PKC isozymes, α, β, δ, ε, γ, and ζ in rat Mas. When compared with control rats, vessels in prenatal testosterone-exposed rats showed significantly increased expression levels of only PKCδ (1.5-fold; Figure 2 ; P<0.05; n=5 in each). Western blotting also showed that PKCδ protein levels were significantly increased (1.7-fold) in the Ma from prenatal testosterone-exposed rats (n=6) than in those from the control (n=6; Figure 3 ; P<0.05). Flutamide administration to prenatal testosterone-exposed rats significantly attenuated the increase in PKCδ protein levels ( Figure 3 ; P<0.05; n=6). PKCδ expression was not significantly different between flutamide-treated prenatal testosterone-exposed rats and flutamide-treated control rats ( Figure 3 ; n=6 in each).
PKCδ-Mediated Vasoconstrictor Responses Were Enhanced in MAs of Hyperandrogenic Prenatal Testosterone-Exposed Females
We next determined the functional implications of increased PKCδ expression in Mas of prenatal testosterone-exposed rats. as shown in Figure 4 , stimulation of PKC with PDBu significantly increased contractile responses with an increase in maximal responses in Mas of prenatal testosterone-exposed rats (27.2±3.5%; n=6) compared with controls (18.7±1.9%; n=8; P<0.05). To further confirm the primary role of PKCδ toward exaggerated vasoconstriction in prenatal testosterone rats, PDBu-induced contractile responses were elicited in the presence of the PKCδ inhibitor, rottlerin. Incubation with rottlerin significantly decreased PDBu-induced contractions in Mas of both control and prenatal testosterone-exposed rats; however, the magnitude of decrease was greater in the arteries of prenatal testosterone-exposed rats than in controls (Figure 4 ; P<0.05; n=6 in each group). These data indicate that PKCδ contributes to exaggerated PDBu-induced contractions in Mas of prenatal testosterone-exposed rats.
Enhanced PKC-mediated contractile responses observed in prenatal testosterone-exposed rats were abrogated after flutamide administration (n=6; 18.6±3.1%; P<0.05; Figure 4 ). However, flutamide administration to control females had no significant effect on PKC-mediated contractile responses (n=6; Figure 4 ). These data indicate that androgens have an underlying role in exaggerated PDBu-induced contraction in prenatal testosterone-exposed rats.
Testosterone Increases PKCδ Gene Expression Levels in Cultured MA Smooth Muscle Cells
Based on the effects of hyperandrogenism on PKCδ expression and contractions in Mas, we next assessed the mechanism of testosterone stimulation of PKCδ expression. We determined the effects of testosterone on PKCδ mRNa and protein levels in an in vitro cell culture model. Both mRNa and protein levels in cultured Ma smooth muscle cells were dose dependently increased by testosterone treatment (Figure 5a and 5B; P<0.005; n=4), indicating that testosterone induces PKCδ expression.
Treatment with testosterone for 5 days also increased the protein levels of aR in a dose-dependent manner with significant increases at 50 and 100 nmol/L in Ma smooth muscle cells (Figure 6 ; P<0.05; n=4).
AR Binding Sites in PKCδ Gene Promoter and Intron 1 Regions
analysis of PKCδ promoter and intron 1 regions showed 6 and 5 androgen response element (aRE)-like sequences, respectively. Putative aREs identified in the promoter region were named p-aRE1 to p-aRE6, and the putative aREs present in intron 1 were named int1-aRE1 to int1-aRE5 ( Figure 7 ; Table S2 in the online-only Data Supplement). We then used the chromatin immunoprecipitation assay to identify if any of these putative aREs interact with aR in the presence of aR-specific ligands. Our results show that putative p-aREs 5,6 and int1-aRE2 interacted with aR in a ligand-dependent fashion. p-aREs 5,6 showed a 2-fold enrichment when treated with testosterone compared with control and flutamide treatment (Figure 8 ; P<0.05; n=4). Interestingly, int1-aRE2 (Figure 8 ; P<0.05; n=4) showed ≈12-fold enrichment in the presence of testosterone compared with vehicle, flutamide, or testosterone+flutamide. However, other predicted putative aREs did not show any ligand-dependent enrichment (data not shown). Thus, our data suggest the presence of functional 
PKCδ Gene Has a Functional Enhancer Element in the Intron 1 Region
We further probed int1-aRE2 because it showed higher fold enrichment. We cloned and sequenced the intron 1 region (GenBank: KF573407.1) and performed a reporter assay. Results show that aR was able to induce transcription in a ligand-dependent manner. Testosterone increased luciferase activity by ≈7-fold and was significantly higher than vehicle and testosterone+flutamide (Figure 9 ; P<0.05; n=4). Thus, our data suggest that the functional aR binding site in the intron 1 region of the PKCδ gene has an enhancer elementlike function.
Discussion
The major finding of this study is the identification of a novel androgen-mediated mechanism that controls the expression of PKCδ in Ma smooth muscle cells by positively regulating PKCδ transcript and protein levels. We identified the functional androgen response and enhancer element that binds aR in response to androgen stimulation in the PKCδ gene promoter and intron 1, respectively. Regulation of PKCδ expression by androgens via the aR has significant functional consequences, as we determined that androgens exert a significant control of PKCδ-mediated arterial contraction and hypertension. Therefore, we suggest that increases in vascular PKCδ-stimulated responses may mediate the development and maintenance of hypertension induced by hyperandrogenism in adult females.
There is mounting evidence that elevated testosterone levels during pregnancy may have adverse effects on fetal growth and thereby increase the potential for an increased risk of cardiovascular diseases in adult life. [3] [4] [5] 43 Consistent with evidence showing that boys and girls of PCOS mothers are often hyperandrogenic, 44, 45 we and others using this model of prenatal androgen exposure have shown that adult females tend to produce higher testosterone compared with controls. We previously reported that hyperandrogenism is associated with increased arterial pressure in prenatal testosterone-exposed adult females. In this study, we show that treatment with the selective aR antagonist flutamide abolished the hypertensive response in prenatal testosterone-exposed adult females. This suggests that aR activation contributes, in part, to the increase in BP in prenatal testosterone-exposed hypertensive adults. The observation that cessation of flutamide treatment reverses BP back to hypertensive levels suggests that testosterone actively regulates BP and that testosterone increase may be a key factor in promoting elevation of BP in the adult prenatal testosterone-exposed females. This is consistent with the growing evidence that shows an important role for androgens in the pathophysiology of hypertension. [20] [21] [22] [23] [24] [25] The question arises as to how androgens provoke increase in BP. Recent studies showed that PKC is a key pathological factor in hypertension. 29, [46] [47] [48] PKC mediates its physiological effects mainly through 13 isoforms, divided into 3 major groups: (1) classical PKC isoforms (α, βI, βII, and γ) requiring both Ca 2+ and diacylglycerol for activation, (2) novel PKC isoforms (δ, ε, η, and θ) requiring only diacylglycerol for activation, and (3) atypical PKC isoforms (λ, μ, and ζ) that are activated by binding phosphatidylserine but not diacylglycerol or Ca
2+
. 49 The α, β, δ, ε, and ζ isoenzymes of PKC have been detected in vascular smooth muscles. 50, 51 although not all of these seem to be in all vascular smooth muscle cells, our studies show presence of all 6 isoenzymes in the Mas, consistent with previous reports. 27 In the present study, we found that only expression of PKCδ was significantly higher in the Mas of hyperandrogenic females. In addition, flutamide treatment reversed the increased PKCδ expression in hyperandrogenic females. These findings suggest that androgens play an important role in stimulating PKCδ expression. This is consistent with the previous findings that coronary PKCδ levels directly correlate with endogenous testosterone levels, 52 and that testosterone increases PKCδ protein levels in coronary smooth muscle of swine. 52, 53 Given the importance of PKCδ in mediating vascular smooth muscle contractile responses, [54] [55] [56] we investigated the functional impact of elevated PKCδ expression. In the present study, PDBu, an activator of PKC, induced contractile responses that were significantly increased in hyperandrogenic rats. The E max were greater in the hyperandrogenic rats and were related to testosterone levels and BP increases. Furthermore, the enhanced vasoconstriction was reversed when the arterial rings were preincubated with rottlerin, suggesting that PKCδ is the primary factor in enhancing vascular contractile responses in hyperandrogenic rats. In fact, previous studies demonstrated that PKCδ located in smooth muscle directly mediates vasocontractile effects. 54, 55, 57 although PKC isoforms have been implicated in contractile responses in dispersed/cultured smooth muscle cells, 58, 59 we think this to be the first instance in which individual PKC isoforms have been specifically identified as being involved in a contractile response in intact vessels, at least when challenged with PDBu. Indeed, the present finding that rottlerin a selective PKCδ inhibitor abrogated hypertension observed in hyperandrogenic rats indicates a causative role of the heightened PKCδ-mediated signaling in the pathogenesis of androgen-induced hypertension. Given that flutamide abolished the exaggerated contractile responsiveness to PDBu in hyperandrogenic rats suggests that the enhanced responsiveness to PKC in these rats is testosterone dependent. This reinforces the notion that modulation of the PKCδ by testosterone contributes to hypertension in prenatal testosterone-exposed female rats.
The finding that testosterone exposure to cultured Ma smooth muscle cells upregulates PKCδ mRNa suggests that PKCδ is a physiological target for testosterone and that androgens can directly regulate the transcription of PKCδ. The question arises as to how androgens regulate PKCδ expression. Our in silico analysis of a 10-kb region upstream of the PKCδ transcription start site revealed 2 tandem aRE-like sequences (p-aREs 5,6) separated by 9 bp located at ≈−4.2 kb resembling the aRE consensus sequence. It is known that steroid receptor binding sites can deviate considerably from the consensus high-affinity motif, and steroid receptor recognition by low-affinity sites can be significantly enhanced by flanking sequences and coregulators. 60, 61 Furthermore, we also found an aRE-like sequence in the intron 1 region of PKCδ (int1-aRE2) at ≈+2.6 kb from the transcriptional start site, which could potentially act as an enhancer element. The presence of enhancers in various regions including in introns has been well documented. 62 Importantly, our chromatin immunoprecipitation studies show that both the p-aREs 5,6 present in the promoter region and int1-aRE2 are efficiently binding to aR in response to testosterone in Ma smooth muscle cells, suggesting that it is functionally relevant in vivo. The luciferase reporter assay of int1-aRE2 showed a ligand-dependent activation, indicating that this sequence is responsive to androgens. androgen-induced upregulation of PKCδ could be mediated by a combination of both direct and indirect effects. Direct effects may be mediated by the cis-acting elements present in the promoter and intron-1 regions, acting as possible response and enhancer elements, respectively. Furthermore, we also show that testosterone upregulates its own receptor, aR in Ma smooth muscle cells there by transregulating PKCδ expression via aR levels. Thus, androgen could potentially regulate the expression of PKCδ by a combination of cis-and transregulation.
although we focused on females in this study, it is possible that androgens exert a similar increases in PKCδ-mediated vasoconstriction in male vasculature as well, which needs further investigation. Thus, in this study, we show that prenatal testosterone treatment induces hyperandrogenism, which controls PKCδ expression via transcriptional regulation to cause enhanced vasoconstriction and hypertension in adult female offspring.
Perspectives
Evidence indicates that androgens can contribute to BP control in women just as in men because young women with conditions such as PCOS, postmenopausal women, and black women have higher plasma testosterone levels, and the frequency of hypertension is greater in these populations. In this study, higher testosterone levels during adult life significantly increases BP. We have shown that PKCδ plays a role in the hypertensive activity of androgen. This study is the first to show the presence of functional androgen response and enhancer elements in the rat PKCδ gene promoter and intron-1, respectively. Regulation of PKCδ expression by androgens via the aR has significant functional consequences, as we determined that androgens exert a significant increase in PKCδ-mediated vasoconstriction. altogether, this study sets forth a novel paradigm suggesting that inhibition of PKCδ can be a potential target for diseases that are regulated by androgen-induced hypertension.
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What Is New?
• Postnatal androgens dynamically regulate blood pressure in hyperandrogenic females.
• Androgen-mediated mechanism controls the expression of protein kinase C (PKC) δ in mesenteric artery smooth muscle cells by positively regulating PKCδ transcript and protein levels
• Functional androgen response and enhancer element binds androgen receptor in response to androgen stimulation in the PKCδ gene promoter and intron 1, respectively.
• Regulation of PKCδ expression by androgens via the androgen receptor has significant functional consequences, as androgens exert a significant control of PKCδ-mediated arterial contraction and blood pressure.
What Is Relevant?
• Sex steroid hormones, including testosterone, have an important influence on blood pressure.
• Hypertension is one of the most common complications during adult life.
• Heightened PKC signaling has been implicated in the development of hypertension.
Summary
The present study provides new evidence in an animal model linking hormonal regulation of PKCδ expression and increased risk of hypertension and reveals a mechanistic understanding of the heightened PKCδ-mediated signaling in the pathogenesis of androgen-induced hypertension. Table: 2 
